MIACALCIN (calcitonin salmon) by Viatris (2) is agonist. Approved for symptomatic paget's disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase, urinary hydroxyproline excretion, postmenopausal osteoporosis in women greater than 5 years postmenopause and 3 more indications. First approved in 1986.
Drug data last refreshed 4h ago · AI intelligence enriched 4w ago
MIACALCIN (calcitonin salmon) is an injectable calcitonin agonist that acts primarily on bone to regulate calcium metabolism. It is indicated for symptomatic Paget's disease of bone, postmenopausal osteoporosis, and acute hypercalcemia. The drug works by binding to calcitonin receptors on osteoclasts and osteoblasts, with greater potency per mg and longer duration than mammalian-origin calcitonins.
Product is approaching loss of exclusivity with minimal current linked job openings, indicating a contracting brand team and transitional commercial phase.
agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer…
Calcitonin
Worked on MIACALCIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MIACALCIN offers limited near-term career expansion given the approaching LOE and minimal current job openings (0 linked positions). This role is best suited for professionals seeking stability in a legacy product environment or those building expertise in lifecycle management and generic transition strategy.